Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Receivables (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Receivables for 6 consecutive years, with $51.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 26.31% year-over-year to $51.0 million, compared with a TTM value of $51.0 million through Dec 2025, up 26.31%, and an annual FY2025 reading of $51.0 million, up 26.31% over the prior year.
  • Receivables was $51.0 million for Q4 2025 at Xeris Biopharma Holdings, down from $53.8 million in the prior quarter.
  • Across five years, Receivables topped out at $53.8 million in Q3 2025 and bottomed at $13.6 million in Q3 2021.
  • Average Receivables over 5 years is $36.1 million, with a median of $38.3 million recorded in 2023.
  • The sharpest move saw Receivables surged 153.91% in 2021, then decreased 10.5% in 2024.
  • Year by year, Receivables stood at $17.5 million in 2021, then skyrocketed by 76.62% to $30.8 million in 2022, then grew by 27.14% to $39.2 million in 2023, then increased by 3.11% to $40.4 million in 2024, then increased by 26.31% to $51.0 million in 2025.
  • Business Quant data shows Receivables for XERS at $51.0 million in Q4 2025, $53.8 million in Q3 2025, and $53.0 million in Q2 2025.